by D'Alto, M. et al.
Department of Cardiology, Second University of Naples, Monaldi Hospital, Naples, Italy
Department of Cardiology, Second University of Naples, Monaldi Hospital, Naples, Italy
After 12months of bosentan therapy, both with and without Down's syndrome patients showed an improvement in WHO functional class (Down: 2.5±0.5 vs 2.9±0.6, p=0.005; controls: 2.5±0.5 vs 2.9±0.5, p=0.000002), 6-minute walk distance (Down: 288±71 vs 239±74m, p=0.0007; controls: 389±80 vs 343±86m, p=0.00003), and hemodynamics (pulmonary flow, Down: 4.0±1.6 vs 3.5±1.4l/m/m(2), p=0.006; controls: 3.5±1.4 vs 2.8±1.0l/m/m(2), p=0.0005; pulmonary to systemic flow ratio, Down: 1.4±0.7 vs 1.0±0.4, p=0.003; controls: 1.1±0.7 vs 0.9±0.3, p=0.012; pulmonary vascular resistance index, Down: 15±9 vs 20±13WUm(2), p=0.007; controls: 20±10 vs 26±15WUm(2), p=0.002).
Int. J. Cardiol. 2011;